{
    "download_date": [
        "ClinicalTrials.gov processed this data on May 09, 2023"
    ],
    "link_text": [
        "Link to the current ClinicalTrials.gov record."
    ],
    "url": [
        "https://clinicaltrials.gov/show/NCT00739739",
        "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4291043&StudyName=An%20Effectiveness%20And%20Safety%20Study%20Of%20PD%200299685%20For%20The%20Treatment%20Of%20Symptoms%20Associated%20With%20Interstitial%20Cystitis"
    ],
    "org_study_id": [
        "A4291043"
    ],
    "nct_id": [
        "NCT00739739"
    ],
    "brief_title": [
        "An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis"
    ],
    "official_title": [
        "A Phase 2, 12 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Proof Of Concept Study Evaluating The Efficacy And Safety Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis/Painful Bladder Syndrome."
    ],
    "lead_sponsor": [],
    "source": [
        "Pfizer"
    ],
    "has_dmc": [
        "No"
    ],
    "textblock": [
        "The purpose of this study is to determine whether PD 0299685 is effective in the treatment of\r\n      symptoms associated with interstitial cystitis/painful bladder syndrome, such as pain,\r\n      urinary urgency and frequency. At the same time assess the drug's safety and tolerability."
    ],
    "overall_status": [
        "Completed"
    ],
    "start_date": [
        "August 2008"
    ],
    "type": [
        "Actual",
        "Actual",
        "Actual",
        "Estimate",
        "Estimate",
        "Estimate"
    ],
    "completion_date": [
        "January 2010"
    ],
    "primary_completion_date": [
        "January 2010"
    ],
    "phase": [
        "Phase 2"
    ],
    "study_type": [
        "Interventional"
    ],
    "has_expanded_access": [
        "No"
    ],
    "allocation": [
        "Randomized"
    ],
    "intervention_model": [
        "Parallel Assignment"
    ],
    "primary_purpose": [
        "Treatment"
    ],
    "masking": [
        "Double (Participant, Investigator)"
    ],
    "measure": [
        "Change from baseline in the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) score.",
        "Change from baseline in worst daily pain severity score as measured by an 11-point Numerical Rating Scale (NRS).",
        "Micturition Diary Variables including frequency, urgency, nocturnal frequency, incontinence episodes.",
        "ICSI at other time points",
        "Interstitial Cystitis Problem Index (ICPI)",
        "Pelvic pain Urgency Frequency score (PUF)",
        "Epworth Sleepiness Scale (ESS)",
        "Columbia-Suicide Severity Rating Scale (C-SSRS)",
        "Adverse events",
        "Physical examination",
        "Vital signs and weight",
        "ECG",
        "Residual urine volume measurement",
        "Global Response assessment (GRA)",
        "Patient Reported Treatment Impact (PRTI)",
        "Treatment failures",
        "Average and worst daily pain score at other time points as measured by an 11-point NRS.",
        "Sleep disturbance and sexual activity pain.",
        "Clinical laboratory tests"
    ],
    "time_frame": [
        "12 WEEKS",
        "12 WEEKS",
        "12 weeks",
        "12 weeks",
        "12 weeks",
        "12 weeks",
        "12 Weeks",
        "15 Weeks",
        "15 Weeks",
        "14 Weeks",
        "15 Weeks",
        "14 Weeks",
        "14 Weeks",
        "12 Weeks",
        "12 Weeks",
        "12 Weeks",
        "12 Weeks",
        "12 Weeks",
        "14 Weeks"
    ],
    "number_of_arms": [
        3.0
    ],
    "enrollment": [
        161.0
    ],
    "condition": [
        "Interstitial Cystitis",
        "Painful Bladder Syndrome"
    ],
    "arm_group_label": [
        "PD 0299685 15mg",
        "PD 0299685 30mg",
        "Placebo",
        "PD 0299685 15mg",
        "PD 0299685 30mg",
        "Placebo"
    ],
    "arm_group_type": [
        "Experimental",
        "Experimental",
        "Placebo Comparator"
    ],
    "intervention_type": [
        "Drug",
        "Drug",
        "Drug"
    ],
    "intervention_name": [
        "PD 0299685 at 15mg BID",
        "PD 0299685 at 30mg BID",
        "placebo for PD 0299685"
    ],
    "description": [
        "5 mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study",
        "10mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study. Initial 2 week titration period at 15mg BID.",
        "Capsules identical in appearance to PD 0299685, 3 to be taken in the morning and at bedtime for the duration of the study",
        "To obtain contact information for a study center near you, click here."
    ],
    "criteria": [],
    "gender": [
        "All"
    ],
    "minimum_age": [
        "18 Years"
    ],
    "maximum_age": [],
    "healthy_volunteers": [
        "No"
    ],
    "last_name": [
        "Pfizer CT.gov Call Center"
    ],
    "role": [
        "Study Director"
    ],
    "affiliation": [
        "Pfizer"
    ],
    "facility": [],
    "country": [
        "United States"
    ],
    "verification_date": [
        "March 2011"
    ],
    "study_first_submitted": [
        "August 20, 2008"
    ],
    "study_first_submitted_qc": [
        "August 20, 2008"
    ],
    "study_first_posted": [
        "August 22, 2008"
    ],
    "disposition_first_submitted": [
        "March 16, 2011"
    ],
    "disposition_first_submitted_qc": [
        "March 16, 2011"
    ],
    "disposition_first_posted": [
        "March 28, 2011"
    ],
    "last_update_submitted": [
        "March 16, 2011"
    ],
    "last_update_submitted_qc": [
        "March 16, 2011"
    ],
    "last_update_posted": [
        "March 28, 2011"
    ],
    "name_title": [
        "Director, Clinical Trial Disclosure Group"
    ],
    "organization": [
        "Pfizer, Inc."
    ],
    "mesh_term": [
        "Pain"
    ]
}